Cargando…
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
BACKGROUND: The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). METHODS: Eligible patients had initiated first-line cytotoxic chemothe...
Autores principales: | O’Shaughnessy, Joyce, Brezden-Masley, Christine, Cazzaniga, Marina, Dalvi, Tapashi, Walker, Graham, Bennett, James, Ohsumi, Shozo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590609/ https://www.ncbi.nlm.nih.gov/pubmed/33109210 http://dx.doi.org/10.1186/s13058-020-01349-9 |
Ejemplares similares
-
Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study
por: Koh, Su-Jin, et al.
Publicado: (2021) -
Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study
por: Koh, Su-Jin, et al.
Publicado: (2021) -
A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status
por: Collins, Jenna M., et al.
Publicado: (2021) -
Breakout Sessions
por: CERN. Geneva
Publicado: (2004) -
Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
por: Yang, Charlie, et al.
Publicado: (2023)